Qiagen and Inovio have announced they will develop a next-generation sequencing (NGS) test for HPV-linked advanced cervical dysplasia that can be used on Illumina's NextSeq 550Dx platform.
The liquid biopsy-based test aims to guide patient selection and offer a noninvasive alternative to having cervical lesions removed. It will be a companion test for Inovio's VGX-3100. Qiagen's expertise in bioinformatics will boost the predictive power of Inovio's preliminary biomarker signature.